Pharsight

Drug Patents owned by Gilead Sciences Inc

1. List of Biktarvy drug patents

BIKTARVY's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7390791 GILEAD SCIENCES INC Prodrugs of phosphonate nucleotide analogues
Apr, 2025

(2 years from now)

US8754065 GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Aug, 2032

(9 years from now)

US9296769 GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Aug, 2032

(9 years from now)

US9216996 GILEAD SCIENCES INC Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepines and methods for treating viral infections
Dec, 2033

(10 years from now)

US9732092 GILEAD SCIENCES INC Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]OXAZEPINES and methods for treating viral infections
Dec, 2033

(10 years from now)

US9708342 GILEAD SCIENCES INC Sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2, 1-b][1, 3]oxazepin-8-olate
Jun, 2035

(12 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7803788 GILEAD SCIENCES INC Prodrugs of phosphonate nucoleotide analogues
Feb, 2022

(1 year, 1 month ago)

US7390791

(Pediatric)

 GILEAD SCIENCES INC Prodrugs of phosphonate nucleotide analogues
Oct, 2025

(2 years from now)

US8754065

(Pediatric)

 GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Feb, 2033

(9 years from now)

US9296769

(Pediatric)

 GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Feb, 2033

(9 years from now)

US10385067 GILEAD SCIENCES INC Sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepin-8-olate
Jun, 2035

(12 years from now)

US10548846 GILEAD SCIENCES INC Therapeutic compositions for treatment of human immunodeficiency virus
Nov, 2036

(13 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Jun 18, 2026
New Chemical Entity Exclusivity (NCE) Feb 7, 2023
M (M) Feb 24, 2024

Drugs and Companies using BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

NCE-1 date: 2022-02-07

Market Authorisation Date: 07 February, 2018

Treatment: Treatment of hiv infection

Dosage: TABLET;ORAL

How can I launch a generic of BIKTARVY before it's patent expiration?
More Information on Dosage

BIKTARVY family patents

45

United States

19

Japan

14

Australia

13

Korea, Republic of

13

European Union

11

China

9

Taiwan, Province of China

9

Canada

8

Mexico

8

Hong Kong

8

Slovenia

8

Hungary

8

Portugal

8

Spain

EA

8

EA

8

New Zealand

7

Denmark

7

Lithuania

7

Croatia

7

Poland

6

Israel

6

Norway

6

Moldova, Republic of

6

Brazil

6

Chile

5

Philippines

5

Costa Rica

5

Argentina

5

Cyprus

5

Peru

5

Ukraine

4

South Africa

4

Uruguay

4

Singapore

3

Morocco

3

Ecuador

3

RS

3

ME

2

El Salvador

2

Turkey

2

Cuba

AP

2

AP

2

Colombia

2

Malaysia

2

Netherlands

2

San Marino

2

Czech Republic

2

Luxembourg

OA

1

OA

1

Belgium

1

Iceland

1

Dominican Republic

1

India

1

Bulgaria

1

Estonia

2. List of Complera drug patents

COMPLERA's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8080551 GILEAD SCIENCES INC HIV inhibiting pyrimidines derivatives
Apr, 2023

(8 days from now)

US7125879 GILEAD SCIENCES INC HIV inhibiting pyrimidines derivatives
Apr, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8101629 GILEAD SCIENCES INC Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
Aug, 2022

(7 months ago)

US9457036 GILEAD SCIENCES INC Compositions and methods for combination antiviral therapy
Jan, 2024

(9 months from now)

US8592397 GILEAD SCIENCES INC Compositions and methods for combination antiviral therapy
Jan, 2024

(9 months from now)

US8716264 GILEAD SCIENCES INC Compositions and methods for combination antiviral therapy
Jan, 2024

(9 months from now)

US9744181 GILEAD SCIENCES INC Compositions and methods for combination antiviral therapy
Jan, 2024

(9 months from now)

US8841310 GILEAD SCIENCES INC Combinations of a pyrimidine containing NNRTI with RT inhibitors
Dec, 2025

(2 years from now)

US10857102 GILEAD SCIENCES INC Therapeutic compositions comprising rilpivirine HCL and tenofovir disoproxil fumarate
Jan, 2033

(9 years from now)

Drugs and Companies using EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE ingredient

Market Authorisation Date: 10 August, 2011

Treatment: Treatment of hiv infection

Dosage: TABLET;ORAL

How can I launch a generic of COMPLERA before it's patent expiration?
More Information on Dosage

COMPLERA family patents

49

United States

25

European Union

20

Norway

19

Japan

14

Australia

13

Hungary

12

China

11

Korea, Republic of

9

Croatia

8

Hong Kong

8

Argentina

8

Brazil

8

Spain

EA

8

EA

7

Denmark

7

Slovenia

7

Poland

7

Taiwan, Province of China

7

Canada

6

Israel

6

Mexico

6

Lithuania

AP

6

AP

6

Portugal

6

New Zealand

5

South Africa

5

Cyprus

5

Luxembourg

5

Ukraine

4

Austria

4

Singapore

3

Belgium

3

Costa Rica

3

Malaysia

3

Peru

2

Germany

2

RS

2

Ecuador

2

Nicaragua

2

ME

OA

1

OA

1

Egypt

1

Jordan

1

Morocco

1

Colombia

1

Netherlands

1

San Marino

1

Iceland

1

Chile

1

Panama

3. List of Descovy drug patents

DESCOVY's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7390791 GILEAD SCIENCES INC Prodrugs of phosphonate nucleotide analogues
Apr, 2025

(2 years from now)

US8754065 GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Aug, 2032

(9 years from now)

US9296769 GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Aug, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7803788 GILEAD SCIENCES INC Prodrugs of phosphonate nucoleotide analogues
Feb, 2022

(1 year, 1 month ago)

US7390791

(Pediatric)

 GILEAD SCIENCES INC Prodrugs of phosphonate nucleotide analogues
Oct, 2025

(2 years from now)

US8754065

(Pediatric)

 GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Feb, 2033

(9 years from now)

US9296769

(Pediatric)

 GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Feb, 2033

(9 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Sep 28, 2024

Drugs and Companies using EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

Market Authorisation Date: 04 April, 2016

Treatment: Treatment of hiv-1 infection; Prophylaxis of hiv-1 infection; Treatment of hiv infection

Dosage: TABLET;ORAL

How can I launch a generic of DESCOVY before it's patent expiration?
More Information on Dosage

DESCOVY family patents

17

United States

9

Japan

6

European Union

5

Australia

5

Norway

4

China

4

Canada

4

New Zealand

3

Denmark

3

Hong Kong

3

Slovenia

3

Lithuania

3

Hungary

3

Croatia

3

Portugal

3

Cyprus

3

Spain

3

Korea, Republic of

2

South Africa

2

Mexico

AP

2

AP

2

Brazil

2

Poland

2

Czech Republic

2

Ukraine

EA

2

EA

1

Israel

OA

1

OA

1

Turkey

1

Belgium

1

Morocco

1

Uruguay

1

Costa Rica

1

Moldova, Republic of

1

Singapore

1

Colombia

1

Argentina

1

Netherlands

1

Peru

1

San Marino

1

Iceland

1

Chile

1

RS

1

Taiwan, Province of China

1

Luxembourg

1

India

1

Ecuador

1

Bulgaria

1

Estonia

1

ME

4. List of Epclusa drug patents

EPCLUSA's oppositions filed in EPO
EPCLUSA Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8580765 GILEAD SCIENCES INC NA
Mar, 2028

(4 years from now)

US9085573 GILEAD SCIENCES INC NA
Mar, 2028

(4 years from now)

US8334270 GILEAD SCIENCES INC NA
Mar, 2028

(4 years from now)

US8633309 GILEAD SCIENCES INC Nucleoside phosphoramidates
Mar, 2029

(5 years from now)

US7964580 GILEAD SCIENCES INC NA
Mar, 2029

(5 years from now)

US9284342 GILEAD SCIENCES INC Nucleoside phosphoramidates
Sep, 2030

(7 years from now)

US8618076 GILEAD SCIENCES INC Nucleoside phosphoramidates
Dec, 2030

(7 years from now)

US8575135 GILEAD SCIENCES INC Antiviral compounds
Nov, 2032

(9 years from now)

US8940718 GILEAD SCIENCES INC Antiviral compounds
Nov, 2032

(9 years from now)

US8921341 GILEAD SCIENCES INC Antiviral compounds
Nov, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8735372 GILEAD SCIENCES INC NA
Mar, 2028

(4 years from now)

US9085573

(Pediatric)

 GILEAD SCIENCES INC NA
Sep, 2028

(5 years from now)

US8580765

(Pediatric)

 GILEAD SCIENCES INC NA
Sep, 2028

(5 years from now)

US8334270

(Pediatric)

 GILEAD SCIENCES INC NA
Sep, 2028

(5 years from now)

US8735372

(Pediatric)

 GILEAD SCIENCES INC NA
Sep, 2028

(5 years from now)

US8889159 GILEAD SCIENCES INC Compositions and methods for treating hepatitis C virus
Mar, 2029

(5 years from now)

US7964580

(Pediatric)

 GILEAD SCIENCES INC NA
Sep, 2029

(6 years from now)

US8889159

(Pediatric)

 GILEAD SCIENCES INC Compositions and methods for treating hepatitis C virus
Sep, 2029

(6 years from now)

US8633309

(Pediatric)

 GILEAD SCIENCES INC Nucleoside phosphoramidates
Sep, 2029

(6 years from now)

US9284342

(Pediatric)

 GILEAD SCIENCES INC Nucleoside phosphoramidates
Mar, 2031

(7 years from now)

US8618076

(Pediatric)

 GILEAD SCIENCES INC Nucleoside phosphoramidates
Jun, 2031

(8 years from now)

US8575135

(Pediatric)

 GILEAD SCIENCES INC Antiviral compounds
May, 2033

(10 years from now)

US8921341

(Pediatric)

 GILEAD SCIENCES INC Antiviral compounds
May, 2033

(10 years from now)

US8940718

(Pediatric)

 GILEAD SCIENCES INC Antiviral compounds
May, 2033

(10 years from now)

US9757406 GILEAD SCIENCES INC Combination formulation of two antiviral compounds
Jan, 2034

(10 years from now)

US11116783 GILEAD SCIENCES INC Combination formulation of two antiviral compounds
Jan, 2034

(10 years from now)

US10086011 GILEAD SCIENCES INC Combination formulation of two antiviral compounds
Jan, 2034

(10 years from now)

US11116783

(Pediatric)

 GILEAD SCIENCES INC Combination formulation of two antiviral compounds
Jul, 2034

(11 years from now)

US10086011

(Pediatric)

 GILEAD SCIENCES INC Combination formulation of two antiviral compounds
Jul, 2034

(11 years from now)

US9757406

(Pediatric)

 GILEAD SCIENCES INC Combination formulation of two antiviral compounds
Jul, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Jun 10, 2028
M (M) Apr 27, 2025
Pediatric Exclusivity (PED) Dec 10, 2028

Drugs and Companies using SOFOSBUVIR; VELPATASVIR ingredient

Market Authorisation Date: 10 June, 2021

Treatment: For the treatment of hepatitis c

Dosage: PELLETS;ORAL

More Information on Dosage

EPCLUSA family patents

92

United States

31

Japan

31

European Union

22

Korea, Republic of

20

China

18

Hong Kong

18

Spain

18

Canada

17

New Zealand

16

Singapore

15

Australia

15

Portugal

13

Slovenia

13

Poland

13

Taiwan, Province of China

12

Israel

12

Mexico

EA

12

EA

11

Brazil

10

Argentina

10

Chile

7

South Africa

7

Denmark

7

Hungary

7

Uruguay

7

Colombia

7

Croatia

7

Cyprus

6

Peru

6

Ecuador

5

Lithuania

5

Philippines

5

Costa Rica

5

RS

5

Ukraine

4

Russia

4

Moldova, Republic of

4

Malaysia

4

ME

3

Morocco

3

Germany

3

San Marino

1

Turkey

1

Norway

AP

1

AP

1

Netherlands

1

Luxembourg

5. List of Genvoya drug patents

GENVOYA's oppositions filed in EPO
GENVOYA Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7390791 GILEAD SCIENCES INC Prodrugs of phosphonate nucleotide analogues
Apr, 2025

(2 years from now)

US7176220 GILEAD SCIENCES INC 4-oxoquinoline compound and use thereof as pharmaceutical agent
Aug, 2026

(3 years from now)

US8981103 GILEAD SCIENCES INC Stable crystal of 4-oxoquinoline compound
Oct, 2026

(3 years from now)

US7635704 GILEAD SCIENCES INC Stable crystal of 4-oxoquinoline compound
Oct, 2026

(3 years from now)

US8148374 GILEAD SCIENCES INC Modulators of pharmacokinetic properties of therapeutics
Sep, 2029

(6 years from now)

US9296769 GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Aug, 2032

(9 years from now)

US8754065 GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Aug, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7803788 GILEAD SCIENCES INC Prodrugs of phosphonate nucoleotide analogues
Feb, 2022

(1 year, 1 month ago)

US7390791

(Pediatric)

 GILEAD SCIENCES INC Prodrugs of phosphonate nucleotide analogues
Oct, 2025

(2 years from now)

US7176220

(Pediatric)

 GILEAD SCIENCES INC 4-oxoquinoline compound and use thereof as pharmaceutical agent
Feb, 2027

(3 years from now)

US8981103

(Pediatric)

 GILEAD SCIENCES INC Stable crystal of 4-oxoquinoline compound
Apr, 2027

(4 years from now)

US7635704

(Pediatric)

 GILEAD SCIENCES INC Stable crystal of 4-oxoquinoline compound
Apr, 2027

(4 years from now)

US9891239 GILEAD SCIENCES INC Modulators of pharmacokinetic properties of therapeutics
Sep, 2029

(6 years from now)

US9891239

(Pediatric)

 GILEAD SCIENCES INC Modulators of pharmacokinetic properties of therapeutics
Mar, 2030

(6 years from now)

US8148374

(Pediatric)

 GILEAD SCIENCES INC Modulators of pharmacokinetic properties of therapeutics
Mar, 2030

(6 years from now)

US8633219 GILEAD SCIENCES INC Combination therapy
Apr, 2030

(7 years from now)

US8633219

(Pediatric)

 GILEAD SCIENCES INC Combination therapy
Oct, 2030

(7 years from now)

US10039718 GILEAD SCIENCES INC Use of solid carrier particles to improve the processability of a pharmaceutical agent
Oct, 2032

(9 years from now)

US8754065

(Pediatric)

 GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Feb, 2033

(9 years from now)

US9296769

(Pediatric)

 GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Feb, 2033

(9 years from now)

US10039718

(Pediatric)

 GILEAD SCIENCES INC Use of solid carrier particles to improve the processability of a pharmaceutical agent
Apr, 2033

(10 years from now)

Drugs and Companies using COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

Market Authorisation Date: 05 November, 2015

Treatment: Treatment of hiv infection; Treatment of hiv infection using a composition containing a pharmacokinetic enhancer that inhibits cytochrome p450 monooxygenase

Dosage: TABLET;ORAL

More Information on Dosage

GENVOYA family patents

65

United States

36

European Union

35

Japan

23

Norway

17

Australia

17

Spain

15

Hungary

15

Portugal

15

Korea, Republic of

15

China

14

Lithuania

13

Denmark

13

Slovenia

13

Croatia

12

Hong Kong

12

Cyprus

12

New Zealand

11

Poland

11

Canada

10

Argentina

9

Mexico

9

Singapore

EA

9

EA

8

Brazil

8

Taiwan, Province of China

AP

7

AP

7

RS

6

South Africa

6

Ukraine

6

ME

5

Israel

5

Peru

4

Luxembourg

3

Colombia

3

Czech Republic

3

Ecuador

2

Turkey

2

Russia

2

Uruguay

2

Malaysia

2

Netherlands

2

San Marino

2

Chile

OA

1

OA

1

Austria

1

Slovakia

1

Belgium

1

Morocco

1

Costa Rica

1

Germany

1

Moldova, Republic of

1

Iceland

1

India

1

Bulgaria

1

Estonia

6. List of Harvoni drug patents

HARVONI's oppositions filed in EPO
HARVONI Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9085573 GILEAD SCIENCES INC NA
Mar, 2028

(4 years from now)

US8580765 GILEAD SCIENCES INC NA
Mar, 2028

(4 years from now)

US8334270 GILEAD SCIENCES INC NA
Mar, 2028

(4 years from now)

US8633309 GILEAD SCIENCES INC Nucleoside phosphoramidates
Mar, 2029

(5 years from now)

US7964580 GILEAD SCIENCES INC NA
Mar, 2029

(5 years from now)

US8822430 GILEAD SCIENCES INC Antiviral compounds
May, 2030

(7 years from now)

US8088368 GILEAD SCIENCES INC Antiviral compounds
May, 2030

(7 years from now)

US9284342 GILEAD SCIENCES INC Nucleoside phosphoramidates
Sep, 2030

(7 years from now)

US8618076 GILEAD SCIENCES INC Nucleoside phosphoramidates
Dec, 2030

(7 years from now)

US10039779 GILEAD SCIENCES INC Combination formulation of two antiviral compounds
Jan, 2034

(10 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8735372 GILEAD SCIENCES INC NA
Mar, 2028

(4 years from now)

US8334270

(Pediatric)

 GILEAD SCIENCES INC NA
Sep, 2028

(5 years from now)

US8735372

(Pediatric)

 GILEAD SCIENCES INC NA
Sep, 2028

(5 years from now)

US8580765

(Pediatric)

 GILEAD SCIENCES INC NA
Sep, 2028

(5 years from now)

US9085573

(Pediatric)

 GILEAD SCIENCES INC NA
Sep, 2028

(5 years from now)

US8889159 GILEAD SCIENCES INC Compositions and methods for treating hepatitis C virus
Mar, 2029

(5 years from now)

US8889159

(Pediatric)

 GILEAD SCIENCES INC Compositions and methods for treating hepatitis C virus
Sep, 2029

(6 years from now)

US7964580

(Pediatric)

 GILEAD SCIENCES INC NA
Sep, 2029

(6 years from now)

US8633309

(Pediatric)

 GILEAD SCIENCES INC Nucleoside phosphoramidates
Sep, 2029

(6 years from now)

US8841278 GILEAD SCIENCES INC Antiviral compounds
May, 2030

(7 years from now)

US8273341 GILEAD SCIENCES INC Antiviral compounds
May, 2030

(7 years from now)

US9511056 GILEAD SCIENCES INC Antiviral compounds
May, 2030

(7 years from now)

US8273341

(Pediatric)

 GILEAD SCIENCES INC Antiviral compounds
Nov, 2030

(7 years from now)

US8841278

(Pediatric)

 GILEAD SCIENCES INC Antiviral compounds
Nov, 2030

(7 years from now)

US8088368

(Pediatric)

 GILEAD SCIENCES INC Antiviral compounds
Nov, 2030

(7 years from now)

US9511056

(Pediatric)

 GILEAD SCIENCES INC Antiviral compounds
Nov, 2030

(7 years from now)

US8822430

(Pediatric)

 GILEAD SCIENCES INC Antiviral compounds
Nov, 2030

(7 years from now)

US9284342

(Pediatric)

 GILEAD SCIENCES INC Nucleoside phosphoramidates
Mar, 2031

(7 years from now)

US8618076

(Pediatric)

 GILEAD SCIENCES INC Nucleoside phosphoramidates
Jun, 2031

(8 years from now)

US9393256 GILEAD SCIENCES INC Methods for treating HCV
Sep, 2032

(9 years from now)

US10456414 GILEAD SCIENCES INC Methods for treating HCV
Sep, 2032

(9 years from now)

US9393256

(Pediatric)

 GILEAD SCIENCES INC Methods for treating HCV
Mar, 2033

(9 years from now)

US10039779

(Pediatric)

 GILEAD SCIENCES INC Combination formulation of two antiviral compounds
Jul, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
ODE* (ODE*) Aug 28, 2026
Orphan Drug Exclusivity (ODE) Apr 7, 2024
Pediatric Exclusivity (PED) Oct 7, 2024

Drugs and Companies using LEDIPASVIR; SOFOSBUVIR ingredient

Market Authorisation Date: 10 October, 2014

Treatment: For the treatment of hepatitis c; For the treatment of genotype 1, 4, 5 or 6 chronic hepatitis c virus (hcv) infection; For treatment-naive genotype 1 patients with chronic hepatitis c virus (hcv) inf...

Dosage: TABLET;ORAL

More Information on Dosage

HARVONI family patents

81

United States

30

Japan

29

European Union

27

China

23

Korea, Republic of

19

Hong Kong

19

Taiwan, Province of China

17

Spain

16

Singapore

15

Canada

14

Israel

14

Mexico

14

Brazil

14

Portugal

14

New Zealand

EA

13

EA

12

Australia

12

Slovenia

12

Poland

11

Chile

10

Hungary

10

Argentina

9

Denmark

9

Croatia

9

Cyprus

8

South Africa

8

Lithuania

7

Uruguay

7

Colombia

7

Peru

6

Ecuador

6

RS

6

Ukraine

6

ME

5

Philippines

5

Costa Rica

4

Russia

4

Norway

4

Malaysia

4

San Marino

3

Germany

3

Moldova, Republic of

2

Morocco

AP

2

AP

2

Netherlands

1

Turkey

1

Luxembourg

7. List of Odefsey drug patents

ODEFSEY's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8080551 GILEAD SCIENCES INC HIV inhibiting pyrimidines derivatives
Apr, 2023

(8 days from now)

US7390791 GILEAD SCIENCES INC Prodrugs of phosphonate nucleotide analogues
Apr, 2025

(2 years from now)

US7125879 GILEAD SCIENCES INC HIV inhibiting pyrimidines derivatives
Apr, 2025

(2 years from now)

US8754065 GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Aug, 2032

(9 years from now)

US9296769 GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Aug, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7803788 GILEAD SCIENCES INC Prodrugs of phosphonate nucoleotide analogues
Feb, 2022

(1 year, 1 month ago)

US8101629 GILEAD SCIENCES INC Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
Aug, 2022

(7 months ago)

US7390791

(Pediatric)

 GILEAD SCIENCES INC Prodrugs of phosphonate nucleotide analogues
Oct, 2025

(2 years from now)

US9296769

(Pediatric)

 GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Feb, 2033

(9 years from now)

US8754065

(Pediatric)

 GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Feb, 2033

(9 years from now)

Drugs and Companies using EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

Market Authorisation Date: 01 March, 2016

Treatment: Treatment of hiv infection

Dosage: TABLET;ORAL

How can I launch a generic of ODEFSEY before it's patent expiration?
More Information on Dosage

ODEFSEY family patents

47

United States

25

European Union

21

Norway

18

Japan

16

Hungary

13

Australia

11

China

10

Korea, Republic of

9

Lithuania

9

Croatia

9

Spain

8

Denmark

8

Hong Kong

8

Slovenia

8

Brazil

8

Canada

8

New Zealand

7

Portugal

6

Mexico

AP

6

AP

6

Cyprus

6

Poland

6

Luxembourg

EA

6

EA

5

Israel

5

South Africa

5

Taiwan, Province of China

5

Ukraine

4

Belgium

4

Argentina

3

Austria

3

Costa Rica

OA

2

OA

2

Singapore

2

Malaysia

2

Netherlands

2

Czech Republic

2

RS

2

Nicaragua

2

ME

1

Turkey

1

Egypt

1

Jordan

1

Morocco

1

Uruguay

1

Germany

1

Moldova, Republic of

1

Colombia

1

Peru

1

San Marino

1

Iceland

1

Chile

1

India

1

Ecuador

1

Bulgaria

1

Estonia

1

Panama

8. List of Sovaldi drug patents

SOVALDI's oppositions filed in EPO
SOVALDI Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8334270 GILEAD SCIENCES INC NA
Mar, 2028

(4 years from now)

US8580765 GILEAD SCIENCES INC NA
Mar, 2028

(4 years from now)

US9085573 GILEAD SCIENCES INC NA
Mar, 2028

(4 years from now)

US7964580 GILEAD SCIENCES INC NA
Mar, 2029

(5 years from now)

US8633309 GILEAD SCIENCES INC Nucleoside phosphoramidates
Mar, 2029

(5 years from now)

US9284342 GILEAD SCIENCES INC Nucleoside phosphoramidates
Sep, 2030

(7 years from now)

US8618076 GILEAD SCIENCES INC Nucleoside phosphoramidates
Dec, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8580765

(Pediatric)

 GILEAD SCIENCES INC NA
Sep, 2028

(5 years from now)

US8334270

(Pediatric)

 GILEAD SCIENCES INC NA
Sep, 2028

(5 years from now)

US9085573

(Pediatric)

 GILEAD SCIENCES INC NA
Sep, 2028

(5 years from now)

US9549941 GILEAD SCIENCES INC Compositions and methods for treating hepatitis C virus
Mar, 2029

(5 years from now)

US8889159 GILEAD SCIENCES INC Compositions and methods for treating hepatitis C virus
Mar, 2029

(5 years from now)

US8889159

(Pediatric)

 GILEAD SCIENCES INC Compositions and methods for treating hepatitis C virus
Sep, 2029

(6 years from now)

US7964580

(Pediatric)

 GILEAD SCIENCES INC NA
Sep, 2029

(6 years from now)

US8633309

(Pediatric)

 GILEAD SCIENCES INC Nucleoside phosphoramidates
Sep, 2029

(6 years from now)

US9549941

(Pediatric)

 GILEAD SCIENCES INC Compositions and methods for treating hepatitis C virus
Sep, 2029

(6 years from now)

US9284342

(Pediatric)

 GILEAD SCIENCES INC Nucleoside phosphoramidates
Mar, 2031

(7 years from now)

US8618076

(Pediatric)

 GILEAD SCIENCES INC Nucleoside phosphoramidates
Jun, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Aug 28, 2026
ODE* (ODE*) Apr 7, 2024
Pediatric Exclusivity (PED) Oct 7, 2024

Drugs and Companies using SOFOSBUVIR ingredient

Market Authorisation Date: 28 August, 2019

Treatment: For the treatment of genotype 1, 2, 3 or 4 chronic hepatitis c virus (hcv) infection as a component of a combination antiviral treatment regimen with ribavirin; For the treatment of hepatitis c

Dosage: PELLETS;ORAL

How can I launch a generic of SOVALDI before it's patent expiration?
More Information on Dosage

SOVALDI family patents

56

United States

21

European Union

20

Japan

17

China

14

Hong Kong

12

Singapore

12

Spain

12

Canada

11

Korea, Republic of

10

Brazil

9

Israel

9

Portugal

9

Chile

9

Taiwan, Province of China

9

New Zealand

8

Mexico

8

Argentina

7

South Africa

7

Australia

7

Slovenia

7

Poland

EA

7

EA

6

Colombia

5

Denmark

5

Hungary

5

Uruguay

5

Croatia

5

Cyprus

4

Lithuania

4

Russia

4

Philippines

4

Costa Rica

4

Peru

4

Ecuador

3

Germany

3

Malaysia

3

RS

3

Ukraine

3

ME

2

Morocco

2

Moldova, Republic of

2

San Marino

1

Turkey

1

Norway

AP

1

AP

1

Netherlands

1

Luxembourg

9. List of Stribild drug patents

STRIBILD's oppositions filed in EPO
STRIBILD Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7176220 GILEAD SCIENCES INC 4-oxoquinoline compound and use thereof as pharmaceutical agent
Aug, 2026

(3 years from now)

US8981103 GILEAD SCIENCES INC Stable crystal of 4-oxoquinoline compound
Oct, 2026

(3 years from now)

US7635704 GILEAD SCIENCES INC Stable crystal of 4-oxoquinoline compound
Oct, 2026

(3 years from now)

US8148374 GILEAD SCIENCES INC Modulators of pharmacokinetic properties of therapeutics
Sep, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9744181 GILEAD SCIENCES INC Compositions and methods for combination antiviral therapy
Jan, 2024

(9 months from now)

US8592397 GILEAD SCIENCES INC Compositions and methods for combination antiviral therapy
Jan, 2024

(9 months from now)

US8716264 GILEAD SCIENCES INC Compositions and methods for combination antiviral therapy
Jan, 2024

(9 months from now)

US9457036 GILEAD SCIENCES INC Compositions and methods for combination antiviral therapy
Jan, 2024

(9 months from now)

US7176220

(Pediatric)

 GILEAD SCIENCES INC 4-oxoquinoline compound and use thereof as pharmaceutical agent
Feb, 2027

(3 years from now)

US7635704

(Pediatric)

 GILEAD SCIENCES INC Stable crystal of 4-oxoquinoline compound
Apr, 2027

(4 years from now)

US8981103

(Pediatric)

 GILEAD SCIENCES INC Stable crystal of 4-oxoquinoline compound
Apr, 2027

(4 years from now)

US9891239 GILEAD SCIENCES INC Modulators of pharmacokinetic properties of therapeutics
Sep, 2029

(6 years from now)

US9891239

(Pediatric)

 GILEAD SCIENCES INC Modulators of pharmacokinetic properties of therapeutics
Mar, 2030

(6 years from now)

US8148374

(Pediatric)

 GILEAD SCIENCES INC Modulators of pharmacokinetic properties of therapeutics
Mar, 2030

(6 years from now)

US8633219 GILEAD SCIENCES INC Combination therapy
Apr, 2030

(7 years from now)

US8633219

(Pediatric)

 GILEAD SCIENCES INC Combination therapy
Oct, 2030

(7 years from now)

US10039718 GILEAD SCIENCES INC Use of solid carrier particles to improve the processability of a pharmaceutical agent
Oct, 2032

(9 years from now)

US10039718

(Pediatric)

 GILEAD SCIENCES INC Use of solid carrier particles to improve the processability of a pharmaceutical agent
Apr, 2033

(10 years from now)

Drugs and Companies using COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE ingredient

Market Authorisation Date: 27 August, 2012

Treatment: Treatment of hiv infection; Treatment of hiv infection using a composition containing a pharmacokinetic enhancer that inhibits cytochrome p450 monooxygenase

Dosage: TABLET;ORAL

How can I launch a generic of STRIBILD before it's patent expiration?
More Information on Dosage

STRIBILD family patents

63

United States

34

Japan

34

European Union

22

Norway

15

Australia

15

Spain

15

Korea, Republic of

14

China

13

Portugal

12

Hungary

12

Argentina

12

Croatia

11

Denmark

11

Lithuania

11

Slovenia

11

Poland

10

Hong Kong

10

Cyprus

9

Taiwan, Province of China

EA

9

EA

9

Canada

9

New Zealand

8

Mexico

8

Singapore

7

Brazil

AP

6

AP

6

RS

5

Israel

5

South Africa

5

Ukraine

5

ME

4

Peru

3

Luxembourg

2

Austria

2

Russia

2

Germany

2

Colombia

2

Malaysia

2

Ecuador

1

Slovakia

1

Turkey

1

Uruguay

1

Netherlands

1

San Marino

1

Czech Republic

1

Iceland

1

Chile

10. List of Sunlenca drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9951043 GILEAD SCIENCES INC Therapeutic compounds
Feb, 2034

(10 years from now)

US10071985 GILEAD SCIENCES INC Therapeutic compounds
Aug, 2037

(14 years from now)

US11267799 GILEAD SCIENCES INC Solid forms of an HIV capsid inhibitor
Aug, 2038

(15 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10654827 GILEAD SCIENCES INC Therapeutic compounds
Aug, 2037

(14 years from now)

Drugs and Companies using LENACAPAVIR SODIUM ingredient

Market Authorisation Date: 22 December, 2022

Treatment: In combination with other antiretroviral(s), for the treatment of hiv-1 infection in heavily-treatment experienced adults with multidrug resistant hiv-1 infection

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

11. List of Tybost drug patents

TYBOST's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8148374 GILEAD SCIENCES INC Modulators of pharmacokinetic properties of therapeutics
Sep, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8148374

(Pediatric)

 GILEAD SCIENCES INC Modulators of pharmacokinetic properties of therapeutics
Mar, 2030

(6 years from now)

US10039718 GILEAD SCIENCES INC Use of solid carrier particles to improve the processability of a pharmaceutical agent
Oct, 2032

(9 years from now)

US10039718

(Pediatric)

 GILEAD SCIENCES INC Use of solid carrier particles to improve the processability of a pharmaceutical agent
Apr, 2033

(10 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Aug 22, 2026

Drugs and Companies using COBICISTAT ingredient

Market Authorisation Date: 24 September, 2014

Treatment: Treatment of hiv infection using a composition containing a pharmacokinetic enhancer that inhibits cytochrome p450 monooxygenase

Dosage: TABLET;ORAL

How can I launch a generic of TYBOST before it's patent expiration?
More Information on Dosage

TYBOST family patents

34

United States

18

European Union

16

Japan

12

Spain

11

Hungary

10

Australia

10

Lithuania

10

Norway

10

Portugal

10

Korea, Republic of

9

Croatia

9

China

8

Denmark

8

Slovenia

8

Singapore

8

Poland

7

Hong Kong

7

Cyprus

EA

7

EA

6

New Zealand

5

Mexico

AP

5

AP

5

Argentina

5

RS

5

Taiwan, Province of China

5

Canada

5

ME

4

Brazil

4

Ukraine

3

Israel

2

South Africa

2

Colombia

2

Ecuador

2

Luxembourg

1

Uruguay

1

Netherlands

1

Peru

1

San Marino

1

Chile

12. List of Veklury drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE46762 GILEAD SCIENCES INC 1′-substituted carba-nucleoside analogs for antiviral treatment
Apr, 2029

(6 years from now)

US8318682 GILEAD SCIENCES INC 1′substituted carba-nucleoside analogs for antiviral treatment
Apr, 2029

(6 years from now)

US8008264 GILEAD SCIENCES INC 1′-substituted carba-nucleoside analogs for antiviral treatment
Sep, 2029

(6 years from now)

US10065958 GILEAD SCIENCES INC Methods and compounds for treating Paramyxoviridae virus infections
Sep, 2031

(8 years from now)

US11492353 GILEAD SCIENCES INC Methods and compounds for treating Paramyxoviridae virus infections
Dec, 2031

(8 years from now)

US9949994 GILEAD SCIENCES INC Methods for treating Filoviridae virus infections
Oct, 2035

(12 years from now)

US9724360 GILEAD SCIENCES INC Methods for treating Filoviridae virus infections
Oct, 2035

(12 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10695361 GILEAD SCIENCES INC Methods for treating arenaviridae and coronaviridae virus infections
Sep, 2036

(13 years from now)

US11007208 GILEAD SCIENCES INC Methods for treating arenaviridae and coronaviridae virus infections
Sep, 2036

(13 years from now)

US11382926 GILEAD SCIENCES INC Methods for treating Arenaviridae and Coronaviridae virus infections
Sep, 2036

(13 years from now)

US10675296 GILEAD SCIENCES INC Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections
Jul, 2038

(15 years from now)

US11266681 GILEAD SCIENCES INC Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections
Jul, 2038

(15 years from now)

US11491169 GILEAD SCIENCES INC Remdesivir treatment methods
May, 2041

(18 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Oct 22, 2025
New Patient Population (NPP) Apr 25, 2025
New Dosing Schedule (D) Jan 21, 2025

Drugs and Companies using REMDESIVIR ingredient

NCE-1 date: 2024-10-22

Market Authorisation Date: 22 October, 2020

Treatment: Treatment of coronavirus disease 2019 (covid-19) in adults and pediatric patients (at least 12 years of age and 40 kg) requiring hospitalization; Treatment of coronavirus disease 2019 (covid-19) in no...

Dosage: POWDER;INTRAVENOUS; SOLUTION;INTRAVENOUS

More Information on Dosage

VEKLURY family patents

45

United States

18

Japan

14

Australia

13

China

13

European Union

11

Korea, Republic of

9

Hong Kong

9

Slovenia

9

Portugal

9

Spain

9

Poland

9

Taiwan, Province of China

EA

9

EA

7

Denmark

7

Hungary

7

Morocco

7

Croatia

7

Brazil

7

Canada

6

Mexico

6

Lithuania

6

Argentina

6

Singapore

5

Israel

5

Cyprus

5

Ecuador

5

New Zealand

4

Costa Rica

4

Colombia

4

Peru

4

Ukraine

3

South Africa

AP

3

AP

3

Chile

3

RS

3

ME

2

El Salvador

2

Philippines

2

Uruguay

2

Norway

2

Cuba

1

Turkey

1

Saudi Arabia

1

Moldova, Republic of

1

Netherlands

1

Dominican Republic

13. List of Vemlidy drug patents

VEMLIDY's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7390791 GILEAD SCIENCES INC Prodrugs of phosphonate nucleotide analogues
Apr, 2025

(2 years from now)

US8754065 GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Aug, 2032

(9 years from now)

US9296769 GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Aug, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7803788 GILEAD SCIENCES INC Prodrugs of phosphonate nucoleotide analogues
Feb, 2022

(1 year, 1 month ago)

US7390791

(Pediatric)

 GILEAD SCIENCES INC Prodrugs of phosphonate nucleotide analogues
Oct, 2025

(2 years from now)

US9296769

(Pediatric)

 GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Feb, 2033

(9 years from now)

US8754065

(Pediatric)

 GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Feb, 2033

(9 years from now)

Exclusivity Exclusivity Expiration
M (M) Aug 22, 2023
New Patient Population (NPP) Oct 17, 2025

Drugs and Companies using TENOFOVIR ALAFENAMIDE FUMARATE ingredient

Market Authorisation Date: 10 November, 2016

Treatment: Treatment of chronic hepatitis b in adult patients

Dosage: TABLET;ORAL

How can I launch a generic of VEMLIDY before it's patent expiration?
More Information on Dosage

VEMLIDY family patents

17

United States

9

Japan

6

European Union

5

Australia

5

Norway

4

China

4

Canada

4

New Zealand

3

Denmark

3

Hong Kong

3

Slovenia

3

Lithuania

3

Hungary

3

Croatia

3

Portugal

3

Cyprus

3

Spain

3

Korea, Republic of

2

South Africa

2

Mexico

AP

2

AP

2

Brazil

2

Poland

2

Czech Republic

2

Ukraine

EA

2

EA

1

Israel

OA

1

OA

1

Turkey

1

Belgium

1

Morocco

1

Uruguay

1

Costa Rica

1

Moldova, Republic of

1

Singapore

1

Colombia

1

Argentina

1

Netherlands

1

Peru

1

San Marino

1

Iceland

1

Chile

1

RS

1

Taiwan, Province of China

1

Luxembourg

1

India

1

Ecuador

1

Bulgaria

1

Estonia

1

ME

14. List of Vitekta drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7176220 GILEAD SCIENCES INC 4-oxoquinoline compound and use thereof as pharmaceutical agent
Aug, 2026

(3 years from now)

US8981103 GILEAD SCIENCES INC Stable crystal of 4-oxoquinoline compound
Oct, 2026

(3 years from now)

US7635704 GILEAD SCIENCES INC Stable crystal of 4-oxoquinoline compound
Oct, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7176220

(Pediatric)

 GILEAD SCIENCES INC 4-oxoquinoline compound and use thereof as pharmaceutical agent
Feb, 2027

(3 years from now)

US7635704

(Pediatric)

 GILEAD SCIENCES INC Stable crystal of 4-oxoquinoline compound
Apr, 2027

(4 years from now)

US8981103

(Pediatric)

 GILEAD SCIENCES INC Stable crystal of 4-oxoquinoline compound
Apr, 2027

(4 years from now)

Drugs and Companies using ELVITEGRAVIR ingredient

Market Authorisation Date: 24 September, 2014

Treatment: Treatment of hiv infection

Dosage: TABLET;ORAL

More Information on Dosage

VITEKTA family patents

11

United States

8

Norway

8

Japan

8

European Union

4

Argentina

3

Peru

2

South Africa

2

Denmark

2

Mexico

2

Australia

2

Hong Kong

2

Russia

2

Slovenia

2

Brazil

2

Portugal

2

Cyprus

2

Malaysia

2

Spain

2

Korea, Republic of

2

Taiwan, Province of China

2

China

2

Canada

2

New Zealand

1

Israel

1

Austria

1

Slovakia

1

Turkey

1

Lithuania

1

Hungary

1

Germany

1

Croatia

1

Poland

1

Czech Republic

1

RS

1

Luxembourg

15. List of Vosevi drug patents

VOSEVI's oppositions filed in EPO
VOSEVI Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8735372 GILEAD SCIENCES INC NA
Mar, 2028

(4 years from now)

US8580765 GILEAD SCIENCES INC NA
Mar, 2028

(4 years from now)

US8334270 GILEAD SCIENCES INC NA
Mar, 2028

(4 years from now)

US9085573 GILEAD SCIENCES INC NA
Mar, 2028

(4 years from now)

US9585906 GILEAD SCIENCES INC NA
Mar, 2028

(4 years from now)

US7964580 GILEAD SCIENCES INC NA
Mar, 2029

(5 years from now)

US8889159 GILEAD SCIENCES INC Compositions and methods for treating hepatitis C virus
Mar, 2029

(5 years from now)

US8633309 GILEAD SCIENCES INC Nucleoside phosphoramidates
Mar, 2029

(5 years from now)

US9284342 GILEAD SCIENCES INC Nucleoside phosphoramidates
Sep, 2030

(7 years from now)

US8618076 GILEAD SCIENCES INC Nucleoside phosphoramidates
Dec, 2030

(7 years from now)

US8940718 GILEAD SCIENCES INC Antiviral compounds
Nov, 2032

(9 years from now)

US8921341 GILEAD SCIENCES INC Antiviral compounds
Nov, 2032

(9 years from now)

US9868745 GILEAD SCIENCES INC Antiviral compounds
Nov, 2032

(9 years from now)

US8575135 GILEAD SCIENCES INC Antiviral compounds
Nov, 2032

(9 years from now)

US9296782 GILEAD SCIENCES INC Inhibitors of hepatitis C virus
Jul, 2034

(11 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8957046 GILEAD SCIENCES INC NA
Mar, 2028

(4 years from now)

US8580765

(Pediatric)

 GILEAD SCIENCES INC NA
Sep, 2028

(5 years from now)

US8735372

(Pediatric)

 GILEAD SCIENCES INC NA
Sep, 2028

(5 years from now)

US9085573

(Pediatric)

 GILEAD SCIENCES INC NA
Sep, 2028

(5 years from now)

US8334270

(Pediatric)

 GILEAD SCIENCES INC NA
Sep, 2028

(5 years from now)

US7964580

(Pediatric)

 GILEAD SCIENCES INC NA
Sep, 2029

(6 years from now)

US8633309

(Pediatric)

 GILEAD SCIENCES INC Nucleoside phosphoramidates
Sep, 2029

(6 years from now)

US8889159

(Pediatric)

 GILEAD SCIENCES INC Compositions and methods for treating hepatitis C virus
Sep, 2029

(6 years from now)

US9284342

(Pediatric)

 GILEAD SCIENCES INC Nucleoside phosphoramidates
Mar, 2031

(7 years from now)

US8618076

(Pediatric)

 GILEAD SCIENCES INC Nucleoside phosphoramidates
Jun, 2031

(8 years from now)

US8575135

(Pediatric)

 GILEAD SCIENCES INC Antiviral compounds
May, 2033

(10 years from now)

US8921341

(Pediatric)

 GILEAD SCIENCES INC Antiviral compounds
May, 2033

(10 years from now)

US8940718

(Pediatric)

 GILEAD SCIENCES INC Antiviral compounds
May, 2033

(10 years from now)

US11116783 GILEAD SCIENCES INC Combination formulation of two antiviral compounds
Jan, 2034

(10 years from now)

US11116783

(Pediatric)

 GILEAD SCIENCES INC Combination formulation of two antiviral compounds
Jul, 2034

(11 years from now)

US11338007 GILEAD SCIENCES INC Combination formulation of three antiviral compounds
Jun, 2037

(14 years from now)

US10912814 GILEAD SCIENCES INC Combination formulation of three antiviral compounds
Jun, 2037

(14 years from now)

US11338007

(Pediatric)

 GILEAD SCIENCES INC Combination formulation of three antiviral compounds
Dec, 2037

(14 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 18, 2022

Drugs and Companies using SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR ingredient

NCE-1 date: 2021-07-18

Market Authorisation Date: 18 July, 2017

Treatment: Treatment of adult patients with chronic hcv infection who have genotype 1a or 3 infection and have previously been treated with an hcv regimen containing sofosbuvir without an ns5a inhibitor; Treatme...

Dosage: TABLET;ORAL

More Information on Dosage

VOSEVI family patents

106

United States

36

Japan

36

European Union

26

Korea, Republic of

23

China

22

Australia

21

Spain

20

Hong Kong

20

Singapore

20

Canada

20

New Zealand

17

Portugal

16

Israel

15

Mexico

15

Slovenia

15

Poland

15

Taiwan, Province of China

EA

15

EA

14

Brazil

12

Argentina

11

Chile

9

Denmark

9

Hungary

9

Uruguay

9

Croatia

9

Cyprus

8

Philippines

8

Colombia

7

South Africa

7

Lithuania

7

Peru

7

RS

7

Ecuador

6

Costa Rica

6

Moldova, Republic of

6

Ukraine

6

ME

5

Morocco

5

Malaysia

4

Russia

4

San Marino

3

Germany

AP

2

AP

1

Turkey

1

Norway

1

Netherlands

1

India

1

Luxembourg

16. List of Zydelig drug patents

ZYDELIG's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.